Reverse transcription polymerase chain reaction

Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Standard BioTools, Hyperion, Genomics, Security (finance), Terrorism, Vii, 600 (number), Supplement, Xi, Health, SBI, Appendix, EBITDA, SomaLogic, News, Form 10-Q, GAAP, Intellectual property, Doctor of Philosophy, Original equipment manufacturer, Research, COVID-19, Risk, Marketing, Annual report, Webcast, Form 10-K, Mass cytometry, Depreciation, Egholm, Standard, Total, Table, Investment, XV, Microfluidics, Hart–Scott–Rodino Antitrust Improvements Act, Failure, Reverse transcription polymerase chain reaction, Fine chemical, Bank, Mergers and acquisitions

As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.

Key Points: 
  • As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.
  • An explanation of these non-GAAP financial measures is also included below under the heading “Use of Non-GAAP Financial Information.
  • ET, to discuss third quarter 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis.

Everside Health Announces Launch of COVID-19 Surveillance Testing Solution for Large Employers

Retrieved on: 
Tuesday, January 11, 2022
PCR, Patient, U.S. Department of Labor, Office of Inspector General, Emergency, COVID-19, Patient safety, Occupational Safety and Health Administration, OSHA, Workplace, Mental health, COVID-19 testing, Trade, Office of Inspector General, U.S. Department of Health and Human Services, CAP, Occupational safety and health, Health, Diabetes, Company, Reverse transcription polymerase chain reaction, Mark (given name), Matrix, LLC, Compliance, Solution, Partnership, Physician, Pharmaceutical industry, Health insurance, Medicine

The Solution which saves employers approximately 66% compared to competing testing services is available nationwide, and a growing number of companies, non-profits and labor organizations have already signed up.

Key Points: 
  • The Solution which saves employers approximately 66% compared to competing testing services is available nationwide, and a growing number of companies, non-profits and labor organizations have already signed up.
  • "At Everside, our goal is to keep workforces healthy and active while reducing the total cost of care for patients and employers alike," said Everside Health Chief Product Officer, Wes Donohoe.
  • Competitively priced testing: Everside's Solution is a cost-effective solution that saves employers approximately 66% compared to competing testing services.
  • For companies looking to learn more about Everside's COVID-19 testing Solution and get in touch with a representative, visit www.eversidehealth.com/workplace-covid-19-testing .

Global Clinical Laboratory Service Markets 2021-2028 - Growing Prevalence of Target Diseases Coupled with Rising Demand for Early Disease Diagnostic Tests - ResearchAndMarkets.com

Retrieved on: 
Monday, October 4, 2021
Biotechnology, Diabetes, Health, Cardiology, Adoption, Reverse transcription polymerase chain reaction, PCR, Degenerative disease, Human, Clinical chemistry, WHO, Service provider, Diagnosis, Application, United States Department of Health and Human Services, Stroke, Death, HHS, Data management, CDC, Automation, Diabetes, COVID-19 testing, Growth, Prevalence, Awareness, COVID-19, Technology, Severe acute respiratory syndrome coronavirus 2, Asia, Genetics, Investment, Department, Pharmaceutical industry

Growing prevalence of target diseases such as diabetes and cardiovascular diseases is expected to positively impact the market growth over the forecast period.

Key Points: 
  • Growing prevalence of target diseases such as diabetes and cardiovascular diseases is expected to positively impact the market growth over the forecast period.
  • For instance, according to the WHO, by 2030, cardiovascular diseases are estimated to cause approximately 23.6 million deaths, mainly from heart disease and stroke.
  • According to WHO and CDC, the standard for laboratory diagnosis of COVID-19 is Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for samples collected from the respiratory tract.
  • Such robust investments by government bodies to increase adoption of COVID-19 diagnostic kits by clinics are anticipated to boost segment growth.

Delta Variant? There Are Others. Milford Molecular Diagnostics Laboratory Routinely Diagnoses Variants of SARS-CoV-2, Including Alpha, Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa and Lambda Variants

Retrieved on: 
Thursday, July 29, 2021
Health, Infectious diseases, Branches of biology, Biology, Biotechnology, Life sciences, Molecular biology, Laboratory techniques, Polymerase chain reaction, DNA, Molecular diagnostics, DNA sequencing, Reverse transcription polymerase chain reaction

Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.

Key Points: 
  • Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.
  • View the full release here: https://www.businesswire.com/news/home/20210729006029/en/
    However, he added, there exists no known diagnostic method for these variants in the U.S. for individual patient samples outside of Milford Diagnostics Laboratory.
  • All variants of concern or of interest must have at least one of these 8 mutated amino acids.
  • Milford Molecular Diagnostics Laboratory is CLIA-certified to perform nested RT-PCR/DNA sequencing for diagnosis of SARS-Co-V-2 and reflex spike protein gene sequencing for variant determination.

Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Medical tests, Natural sciences, Life sciences, Biotechnology, Molecular biology, Laboratory techniques, COVID-19, Saliva testing, Reverse transcription polymerase chain reaction, COVID-19 rapid antigen test, Polymerase chain reaction

Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.

Key Points: 
  • Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.
  • "We're excited to share our overall 264 test results from our Brazilian AcuVid Saliva / RT-PCR Test Clinical Study.
  • The additional 201 test results, on top of the initial 63, not only exceed FDA-EUA minimum requirements, but confirms the performance quality and ease-of-use of our AcuVid saliva test.
  • In fact, our complete AcuVid study achieved comparable, and in some cases, better performance results than other leading COVID-19 rapid antigen tests available on today's market," expressed Rob Fia, CEO of Therma Bright.

Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests

Retrieved on: 
Thursday, July 22, 2021
Research, Medical Supplies, Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Branches of biology, Biology, Natural sciences, Molecular biology, Biotechnology, Laboratory techniques, Sarbecovirus, Zoonoses, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, COVID-19

Rates of vaccinations in many countries have slowed, with COVID cases specific to the Delta variant spiking.

Key Points: 
  • Rates of vaccinations in many countries have slowed, with COVID cases specific to the Delta variant spiking.
  • In March 2020, Twist launched its first synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2.
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.
  • For customers interested in alternative variants of SARS-CoV-2, or synthetic RNA or DNA controls for other sequences, Twist can provide custom controls in multiple formats.

Biocept to Participate in Two July Investment Conferences

Retrieved on: 
Monday, July 19, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Branches of biology, Biotechnology, Medical tests, Molecular diagnostics, Liquid biopsy, Biopsy, Reverse transcription polymerase chain reaction, Cerebrospinal fluid

The conference is being held in Newport, R.I. on July 26.

Key Points: 
  • The conference is being held in Newport, R.I. on July 26.
  • Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.
  • In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Quantabio’s UltraPlex 1-Step ToughMix Added to SalivaDirect Emergency Use Authorization Protocol

Retrieved on: 
Monday, July 12, 2021
Science, Biotechnology, Research, Health, FDA, Medical devices, Infectious diseases, Genetics, Natural sciences, Laboratory techniques, Chemistry, Physical sciences, Molecular biology, Polymerase chain reaction, Biotechnology, Amplifiers, Real-time polymerase chain reaction, Assay, Reverse transcription polymerase chain reaction

Authorized CLIA-certified laboratories running the SalivaDirect protocol can now use the UltraPlex 1-Step ToughMix, which was designed to increase sensitivity and improve assay performance, especially when dealing with saliva samples that may contain a low copy number of RNA virus.

Key Points: 
  • Authorized CLIA-certified laboratories running the SalivaDirect protocol can now use the UltraPlex 1-Step ToughMix, which was designed to increase sensitivity and improve assay performance, especially when dealing with saliva samples that may contain a low copy number of RNA virus.
  • The addition of the Quantabio UltraPlex 1-Step ToughMix enhances the protocol by enabling scientists to overcome common PCR inhibitors and quantify RNA viruses with high efficiency, sensitivity and specificity using as little as 1 pg of starting material.
  • Being added to the SalivaDirect EUA protocol is another strong validation of the versatility of our UltraPlex 1-Step ToughMix, said Heather Meehan, PhD, Vice President and Head of Quantabio.
  • UltraPlex 1-Step ToughMix is a ready-to-use, one-step, 4X concentrated RT-qPCR master mix that uses probe-based detection methods for real-time PCR.

Eurofins and Rite Aid Launch an Over-the-Counter, FDA-Authorised, at-Home COVID-19 PCR Test in all Rite Aid Locations in the U.S.

Retrieved on: 
Friday, July 9, 2021
Medical devices, Health, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Articles, Natural sciences, Life sciences, Biotechnology, Laboratory techniques, Molecular biology, COVID-19 testing, Eurofins Scientific, Emergency Use Authorization, COVID-19, Reverse transcription polymerase chain reaction, Polymerase chain reaction

Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit.

Key Points: 
  • Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit.
  • The at-home COVID-19 nasal PCR kit is among the first over-the-counter at-home test kits for SARS-CoV-2 to receive US Food and Drug Administration Emergency Use Authorization (EUA).
  • The test was developed by Eurofins Viracor , a leading infectious disease testing laboratory, and is based on its FDA EUA authorised SARS-CoV-2 RT-PCR assay.
  • Eurofins CEO, Gilles Martin commented: "We are excited to partner with Rite Aid and launch this at-home COVID-19 testing kit, making access to test kits widely available to people across the U.S through Rite Aids national network.

BioGX Receives FDA EUA for a Novel, High-Throughput, Direct Sample RT-PCR Test for COVID-19

Retrieved on: 
Friday, July 2, 2021
Natural sciences, Molecular biology, Laboratory techniques, Articles, Branches of biology, Biotechnology, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction, COVID-19 testing, Real-time polymerase chain reaction, Natural sciences, Molecular biology, Laboratory techniques, Articles, Branches of biology, Biotechnology, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction, COVID-19 testing, Real-time polymerase chain reaction

Xfree COVID-19 is acomplete test lyophilized in a single tube, for extraction-free, direct sample addition real-time RT-PCR testing.

Key Points: 
  • Xfree COVID-19 is acomplete test lyophilized in a single tube, for extraction-free, direct sample addition real-time RT-PCR testing.
  • Matthew Beckman, Ph.D., Director of Laboratory Services at GENETWORx said, "The staff at GENETWORx has been very pleased with the performance of the BioGX Xfree COVID-19 test.
  • BioGX test is very simple to use while providing increased quality assurance of well-by-well monitoring of the PCR reaction.
  • The test is already in use in several laboratories and costs $7-12 per sample depending on its use as direct sample addition or with extracted sample.